|
Impact of early identification of brain metastases in metastatic renal cell carcinoma (mRCC). |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Merck; Novartis; Pfizer; Roche/Genentech; Tersera |
Consulting or Advisory Role - Abbvie; Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck; Pfizer; Roche/Genentech; Tersera |
Research Funding - Bristol-Myers Squibb (Inst); Ipsen; Novartis; Roche |
|
|
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; GlaxoSmithKline/Novartis; Merck; Pfizer |
Consulting or Advisory Role - Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; Merck; Novartis |
Research Funding - Boehringer Ingelheim; Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Novartis (Inst); Roche/Genentech (Inst) |
|
|
Honoraria - AstraZeneca; Eisai; Ipsen; Merck; Novartis; Roche |
Consulting or Advisory Role - Astellas Pharma; Pfizer |
|
|
Research Funding - Aragon Pharmaceuticals (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche Canada (Inst) |
|
|
Honoraria - Astellas Pharma; Eisai; Ipsen; Janssen; Merck; Pfizer |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck; Pfizer; Roche Canada |
Travel, Accommodations, Expenses - Eisai; Janssen |
|
|
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck; Novartis; Pfizer |
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst) |
|
|
No Relationships to Disclose |
|
Christian K. Kollmannsberger |
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer |
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Novartis; Pfizer |
Travel, Accommodations, Expenses - Eisai; Novartis; Pfizer |
|
|
Honoraria - AstraZeneca; Bristol-Myers Squibb; Ipsen; Merck; Novartis; Pfizer; Roche/Genentech |
Consulting or Advisory Role - Ipsen; Merck; Pfizer |
Research Funding - Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Eisai; Ipsen; Janssen Oncology; Novartis; Pfizer |
Research Funding - Bristol-Myers Squibb (Inst) |
|
|
Honoraria - Amgen; Astellas Pharma; Bayer; Janssen; Sanofi |
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Janssen; Progenics; Sanofi |
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Sanofi |
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Sanofi (Inst) |
Expert Testimony - Amgen; Astellas Pharma; Bayer; Sanofi |
Travel, Accommodations, Expenses - Bayer; Sanofi |
|
|
Honoraria - Bristol-Myers Squibb; Eisai; Ipsen; Novartis; Pfizer |
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Ipsen; Novartis; Pfizer |
Research Funding - Merck (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Novartis; Pfizer |